Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
about
The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's DiseaseCerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiencyRealistic expectations of prepulse inhibition in translational models for schizophrenia research.Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegenerationAsialoerythropoietin is not effective in the R6/2 line of Huntington's disease miceGait dynamics in mouse models of Parkinson's disease and Huntington's disease.Dopamine Receptors and NeurodegenerationCRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseasesMouse models of polyglutamine diseases: review and data table. Part IFingolimod for the treatment of neurological diseases-state of play and future perspectivesAlkaline Ceramidase 3 Deficiency Results in Purkinje Cell Degeneration and Cerebellar Ataxia Due to Dyshomeostasis of Sphingolipids in the BrainCorrelations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HDA new drug design targeting the adenosinergic system for Huntington's diseaseRhoE deficiency produces postnatal lethality, profound motor deficits and neurodevelopmental delay in miceN-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's diseaseOral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivoMajor facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolismGeneration and characterization of Rac3 knockout mice.Lack of the central nervous system- and neural crest-expressed forkhead gene Foxs1 affects motor function and body weightP-Rex2 regulates Purkinje cell dendrite morphology and motor coordination.Deficiency of the zinc finger protein ZPR1 causes neurodegenerationAssessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease.High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's DiseaseLimited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph DiseaseTight junctions in Schwann cells of peripheral myelinated axons: a lesson from claudin-19-deficient miceDeficits in a Simple Visual Go/No-go Discrimination Task in Two Mouse Models of Huntington's DiseaseTemporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutationGenetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's diseaseOnset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability.Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocyclinePax2-Islet1 Transgenic Mice Are Hyperactive and Have Altered Cerebellar Foliation.Motor Performance is Impaired Following Vestibular Stimulation in Ageing MiceCalibration of rotational acceleration for the rotarod test of rodent motor coordination.Postanesthetic effects of isoflurane on behavioral phenotypes of adult male C57BL/6J miceGcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model.Decreased anxiety-like behavior and Gαq/11-dependent responses in the amygdala of mice lacking TRPC4 channels.Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome.Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome.Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition
P2860
Q21092845-4A7BD2AD-0DA0-4EC1-B2E9-8C00679CB35AQ24563081-B129FA44-6004-4A51-B083-957084E8B0E7Q24645703-078F013E-5DAC-4E9E-A833-F946415B9297Q24684828-10EF955E-D6D3-41D5-988A-B5637A959518Q24795623-1BEF8938-A16D-45F4-86F4-F703B059E7E6Q24812417-D0C24AB5-3364-420B-B8FE-4297DEA3841BQ26783348-39333124-F1CA-49B8-A905-8C4F8F865B43Q26799640-4F40F620-B866-41A2-8F9A-49884A032211Q26853025-B8F4FAFA-8D3E-4C68-AF87-C9B591EC96E1Q27026175-31C9B00F-755C-4AED-AFA8-CB6F82CC582FQ27310161-5ADAD6CE-BCFF-4D21-864C-84080691E359Q27332203-E92C8DBD-0159-4410-A305-CEF54F7BBCABQ27335053-CE11BA31-57AA-4940-8F33-1632255FE20AQ27345530-6DAAB3B8-5EAB-409D-B9A7-A18548634C44Q28387085-E919B60D-8C0D-45C2-A2D2-4A94CB0A75EEQ28483335-F7B02682-F4A9-473A-B12F-99CE1BC1171BQ28485382-BA9A00BB-71F5-4CDD-987B-B5BBD234494FQ28511522-966A4043-A384-429C-B495-C81D363E8593Q28512033-3B8102B9-300D-4F2F-BEE9-75A502FE2152Q28513238-547629F9-2785-42CE-9290-2CDF99382E6DQ28513750-A194111D-816C-4C69-8CA2-6658AAD138ECQ28534633-67D60A3F-E79C-45AE-857A-204D11A23C17Q28534655-553D2D6D-8694-4BB1-9E13-BEB0E9A2A039Q28550502-A0F56C81-C6A4-4BFF-9FFC-758D11A5CA1DQ28592632-AF8458C3-EE3E-4E7B-8D9E-63F0B70C5740Q28661598-0F6892A0-A5B6-40B2-B2D9-BB87E7E773C5Q28728849-3109E882-E358-4EDB-8B06-F6A44918A392Q28732195-8DACA378-6BCA-487A-9D46-44926747667FQ28741746-9C562889-C56B-4884-84CA-714932669E68Q28748449-3933EC10-3F9A-49FA-8333-42429AAAA133Q30362535-CEF330B0-FE67-46CA-8947-75F286737C87Q30391220-C5311282-4548-4B61-8BE3-84DEB3A988F6Q30415713-DEE82DE3-7D1F-4250-BE36-842C3B346B1FQ30415904-BCDD8C07-9881-450F-B837-3AE127B671C0Q30422849-38DE51ED-279E-4921-86D1-0E17048C25B8Q30431334-FF125ED2-D984-41AC-BB8F-BCFF541DABFBQ30435819-48B45ECB-999D-468F-A10C-01FE64ADDABBQ30452232-99CD8812-0320-40E0-B33C-7ED2606AFC36Q30454136-99703D81-85C1-424A-B75F-F1C0DDFC25E2Q30458275-F983F330-8774-4FF8-8195-1453CF6CA5ED
P2860
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Characterization of progressiv ...... Huntington's disease mutation.
@ast
Characterization of progressiv ...... Huntington's disease mutation.
@en
type
label
Characterization of progressiv ...... Huntington's disease mutation.
@ast
Characterization of progressiv ...... Huntington's disease mutation.
@en
prefLabel
Characterization of progressiv ...... Huntington's disease mutation.
@ast
Characterization of progressiv ...... Huntington's disease mutation.
@en
P2093
P1476
Characterization of progressiv ...... Huntington's disease mutation
@en
P2093
P304
P356
10.1523/JNEUROSCI.19-08-03248.1999
P407
P577
1999-04-01T00:00:00Z